Experimental cell therapy for tough blood cancers put on hold
NCT ID NCT05336409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Oncology Hematology Care, Inc-Kenwood
Cincinnati, Ohio, 45236, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University of California San Diego, Moores Cancer Center
San Diego, California, 92093, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Kentucky - Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
-
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients
- New drug combo aims to tackle Hard-to-Treat lymphoma